Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
Christophe Dubois, Head of the Master’s Degree in Biology and Health, Team leader of Thrombosis and Cancer at Aix Marseille University, shared on LinkedIn:
”It was a real honor and pleasure to chair Nicolas Gendron‘s research accreditation yesterday in the presence of Pascale Gaussem, David Smadja, Sylvie Bouvier, and Marc Vasse!
We discussed NETs, DNase, vascular sequelae, carbon footprints, AOD, animal models, ultrasound, and much more…
The future of hemostasis is assured in France with our young talents!
Bravo Nicolas and Bravo Pascale and David for training him and guiding him to scientific excellence while highlighting his human qualities, which are more essential than ever!
It was a real honor and pleasure to chair yesterday Nicolas Gendron’s HDR defense in the presence of Pascale Gaussem, David Smadja, Sylvie Bouvier, and Marc Vasse!
We discussed NETs, DNase, vascular injury, carbon footprints, DOA, animal models, ultrasound, and much more…
The future of hemostasis is assured in France with our young talents!
Congrats Nicolas, and congratulations to Pascale and David for training him and guiding him to scientific excellence while highlighting his human qualities, which are more essential than ever!”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM
-
Sep 20, 2026, 00:46Julia R. Coleman: Platelet Biology and Sex Differences in the Plasma Milieu at AAST 2026